ClinicalTrials.gg
TerminatedNCT02584634Updated Jul 7, 2023Results posted

Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)

A Phase 1/2 interventional study of Avelumab and PF-06463922 in Non-Small Cell Lung Cancer, sponsored by Pfizer. Terminated at 20 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-07.

Sponsored by Pfizer · Phase 1/2, Interventional, and Treatment

Why this study was terminated
The study was terminated since there was no need for further safety or efficacy data to be collected. The participants having benefit from the Investigational treatments have been moved to a continuation study (NCT05059522)

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
43
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing lorlatinib in Carcinoma, Non-Small-Cell Lung — 8 open to participants now, 16 under way, 1 of them phase 3. lorlatinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
15th of 27
43 · median 45
Started
2015
the only one that year
Phase 1/2
3 of 27
none open now
Registered
2nd of 27
by date
Lead sponsor
8 of 27
Pfizer

Among the 27 studies testing lorlatinib in Carcinoma, Non-Small-Cell Lung, this one is the 15th largest by enrollment, is the only one that started in 2015, is one of 3 in phase 1/2, and was the 2nd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

8 of the 27 studies testing lorlatinib in Carcinoma, Non-Small-Cell Lung are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About lorlatinib

lorlatinib: first FDA approval 2018 (LORBRENA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing lorlatinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of avelumab when combined with either crizotinib or PF-06463922.

Read the detailed description

This is a Phase 1b/2, open label, multi center, multiple dose, safety, pharmacokinetic and pharmacodynamic study of Group A and Group B in cohorts of adult patients with locally advanced or metastatic NSCLC.

03

Conditions studied

  • Non-Small Cell Lung Cancer

Keywords

  • Non-Small Cell Lung Cancer
  • NSCLC
  • ALK
  • avelumab
  • crizotinib
  • PF-06463922
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of advanced or NSCLC. Group A must be ALK negative NSCLC and Group B must be ALK positive NSCLC
  • Group A at least one prior regimen of therapy
  • Group B any number of prior regimens.
  • Mandatory tumor tissue available
  • At least one
  • Performance status 0 or 1
  • Adequate bone marrow, renal, liver and pancreatic function
  • Negative pregnancy test for females of
  • Group B Phase 2: No prior systemic treatment for advanced or metastatic disease ( and/or neoadjuvant therapies are allowed if completed at least 6 months prior to study entry. No prior tyrosine kinase inhibitor therapy is allowed at any time prior to study entry)

Exclusion criteria

Exclusion Criteria:

  • No prior therapy with an , anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody.
  • No Severe or Chronic medical conditions including gastrointestinal abnormalities or significant cardiac history
  • No active infection requiring systemic therapy
  • Prior organ transplantation including allogenic stem cell transplantation.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Group A

    ALK negative Non-Small Cell Lung Cancer

    Drug: Avelumab · Drug: Crizotinib

  • Experimental
    Group B

    ALK positive Non-Small Cell Lung Cancer

    Drug: Avelumab · Drug: PF-06463922

Interventions

  • Administered by IV once every two weeks in doses of either 5 mg/kg or 10 mg/kg

    Also known as: MSB0010718C

  • Tablets taken orally once every day in doses of either 100mg, 75mg, or 50mg.

  • Capsules. Taken orally once or twice every day in doses of either 200mg or 250mg.

    Also known as: PF-02341066

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-limiting Toxicities (DLTs): Phase 1b

    Any of the following adverse events (AEs) occurring during the primary DLT observation period that are attributable to one, the other, or both study drugs were classified as DLTs: Grade 4 (life-threatening) neutropenia if \>7 days in duration; febrile neutropenia; Grade \>=3 (severe or life threatening) neutropenic infection; Grade \>=3 thrombocytopenia with bleeding; Grade 4 thrombocytopenia \>7 days; Grade 4 anemia; any Grade \>=3 toxicity, except for any of the following: transient (\<=6 hours) Grade 3 (severe) flu like symptoms or fever; transient (\<=24 hours) Grade 3 fatigue, local reactions, or headache that resolved to Grade \<=1 (no AE or mild AE); Grade 3 nausea and/or vomiting, diarrhea or skin toxicity that resolved to Grade \<=1 within 7 days; any Grade \>=3 amylase or lipase abnormality; tumor flare phenomenon; single laboratory values out of normal range that were not related to treatment, did not have any clinical correlate, and resolve to Grade \<=1 within 7 days.

    Time frame: First 2 cycles (1 cycle = 14 days)

  2. Percentage of Participants With Objective Response (OR): Phase 2

    OR is defined as complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 from start date (the date of first dose of study treatment) until disease progression or death due to any cause. Both CR and PR must be confirmed by repeat assessments performed no less than 4 weeks after the criteria for response are first met. Per RECIST v1.1: CR is defined as the disappearance of all target or non-target lesions; any pathological lymph nodes (whether target or non target) must have reduction in short axis to \<10 mm and all lymph nodes must be non-pathological in size (\<10 mm short axis). PR is defined as a \>=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.

    Time frame: Screening, Day 1 of each cycle starting Cycle 3, up to end of treatment/withdrawal (maximum of 5 years)

  3. Percentage of Participants With CR for Group B: Phase 2

    Per RECIST v1.1: CR is defined as the disappearance of all target or non-target lesions; any pathological lymph nodes (whether target or non target) must have reduction in short axis to \<10 mm and all lymph nodes must be non-pathological in size (\<10 mm short axis).

    Time frame: Baseline up to 60 months

Secondary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    TEAEs are those events with onset dates occurring during the on-treatment period for the first time, or if the worsening of an event is during the on-treatment period. Treatment-related AEs was any untoward medical occurrence attributed to study drug in a participant who received study drug. Per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03: Grade 3 (Severe) events=unacceptable or intolerable events, significantly interrupting usual daily activity, require systemic drug therapy/other treatment; Grade 4 (Life-threatening) events caused participant to be in imminent danger of death; Grade 5 (Death) events=death related to an AE. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in participant hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

    Time frame: Baseline up to 30 days after last dose of study treatment or the day before start day of new anti-cancer therapy (maximum of 5 years)

  2. Number of Participants With Baseline Laboratory Abnormalities Grade <=2 and Post-Baseline Laboratory Abnormalities of Grades 3 or 4 Per NCI CTCAE v4.03

    The laboratory results were graded according to the NCI CTCAE v4.03 severity grade. Grade 1=mild AE. Grade 2=moderate AE. Grade 3=severe AE. Grade 4=life-threatening consequences; urgent intervention indicated. Shift tables were provided to examine the distribution of laboratory toxicities. The following parameters had met the criteria of CTCAE grade shift change from Grade \<=2 at baseline to Grade 3 or 4 post baseline: anemia, lymphocyte count decreased, lymphocyte count decreased, neutrophil count decreased, white blood cell decreased, alanine aminotransferase increased, aspartate aminotransferase increased, blood bilirubin increased, cholesterol high, Creatine phosphokinase (CPK) increased, Gamma glutamyl transferase (GGT) increased, hypercalcemia, hyperglycemia, hypermagnesemia, hypertriglyceridemia, hypoalbuminemia, hyponatremia, lipase increased, serum amylase increased. Baseline is defined as the last assessment prior to the date/time of the first dose of study treatment.

    Time frame: Screening up to end of treatment/withdrawal (maximum of 5 years)

  3. Number of Participants With Vital Signs Meeting Pre-defined Criteria

    Pre-defined criteria in vital signs: pulse rate \<50 beats per minute, pulse rate \>120 bpm, sitting diastolic blood pressure (DBP) increase and decrease in change from baseline of \>= 20 millimeter of mercury (mmHg), sitting systolic blood pressure(SBP) \< 90 mmHg, increase and decrease in change from baseline of \>= 30mmHg. Baseline is defined as the last assessment prior to the date/time of the first dose of study treatment.

    Time frame: Screening up to end of treatment/withdrawal (maximum of 5 years)

  4. Disease Control Rate (DCR)

    DC is defined as objective response (CR or PR) or stable disease (SD) per RECIST v.1.1 from the date of first dose of study treatment until disease progression or death due to any cause. The DCR is the proportion of patients with DC. Per RECIST v1.1: CR is defined as the disappearance of all target or non-target lesions; any pathological lymph nodes (whether target or non target) must have reduction in short axis to \<10 mm. PR is defined as a \>=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD). PD is defined as a \>=20% increase in the sum of the longest dimensions of the target lesions taking as a reference the smallest sum of the longest dimensions recorded since the treatment started, or the appearance of one or more new lesions.

    Time frame: Screening, Day 1 of each cycle starting Cycle 3, up to end of treatment/withdrawal (maximum of 5 years)

  5. Duration of Response (DR)

    DR: time from first documented occurrence of response (PR or CR) until date of first documented PD or death due to underlying cancer. Per RECIST 1.1: CR: disappearance of all non-nodal target lesions and of all non-target lesions; any pathological lymph nodes assigned as target lesions/non-target lesions have a reduction in short axis to \<10 mm. PR: at least a \>=30% decrease in sum of diameter of all target lesions, taking as reference baseline sum of diameters. PD: at least a \>=20% increase in sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, sum must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of existing non-target lesions. Appearance of new lesions. Participants with no PD and were still alive by 02 Feb 2020, were censored at last adequate tumor assessment. Kaplan-Meier method was used for DR analysis.

    Time frame: Screening, Day 1 of each cycle starting Cycle 3, up to end of treatment/withdrawal (maximum of 5 years)

  6. Time to Tumor Response (TTR)

    TTR is defined, for participants with an objective response (CR or PR), as the time from the start date (the date of first dose of treatment) to the first documentation of objective response (CR or PR) which is subsequently confirmed. Per RECIST v1.1: CR: disappearance of all non-nodal target lesions and of all non-target lesions. In addition, any pathological lymph nodes assigned as target lesions/ non-target lesions must have a reduction in short axis to \<10 mm. PR: at least a 30% decrease in sum of diameter of all target lesions, taking as reference baseline sum of diameters.

    Time frame: Screening, Day 1 of each cycle starting Cycle 3, up to end of treatment/withdrawal (maximum of 5 years)

  7. Progression-free Survival (PFS)

    PFS is defined as the time from start date (the date of first dose of treatment) to the date of the first documentation of PD per RECIST v1.1 or death due to any cause, whichever occurs first. Per RECIST v1.1: PD: a \>=20% increase in the sum of the longest dimensions of the target lesions taking as a reference the smallest sum of the longest dimensions recorded since the treatment started, or the appearance of one or more new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: Screening, Day 1 of each cycle starting Cycle 3, up to end of treatment/withdrawal (maximum of 5 years)

  8. Kaplan-Meier Estimates of Overall Survival (OS)

    OS is defined as the time from start date (the date of first dose of treatment) to the date of death due to any cause.

    Time frame: Screening, Day 1 of each cycle starting Cycle 3, up to end of treatment/withdrawal (maximum of 5 years)

  9. Maximum Plasma Concentration (Cmax) of Crizotinib in The Presence of Avelumab

    Cmax of crizotinib in the presence of avelumab was observed directly from data.

    Time frame: Pre-dose, 1, 2, 4, 6 and 8 hours post dose on Day 1 of Cycle 2

  10. Time to Cmax (Tmax) of Crizotinib in The Presence of Avelumab

    Tmax of crizotinib in the presence of avelumab was observed directly from data as time of first occurrence.

    Time frame: Pre-dose, 1, 2, 4, 6 and 8 hours post dose on Day 1 of Cycle 2

  11. Area Under The Plasma Concentration-Time Curve During The Dosing Interval Time Course (AUCtau) of Crizotinib in The Presence of Avelumab

    AUCtau of crizotinib in the presence of avelumab was calculated by Linear/Log trapezoidal method. Dose interval is defined as after single dose from time zero to the next dose (after single dose and at steady state).

    Time frame: Pre-dose, 1, 2, 4, 6 and 8 hours post dose on Day 1 of Cycle 2

  12. Apparent Plasma Clearance (CL/F) of Crizotinib in The Presence of Avelumab

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

    Time frame: Pre-dose, 1, 2, 4, 6 and 8 hours post dose on Day 1 of Cycle 2

  13. Cmax of Crizotinib Metabolite PF-06260182 in The Presence of Avelumab

    Cmax of crizotinib metabolite PF-06260182 in the presence of avelumab was observed directly from data.

    Time frame: Pre-dose, 1, 2, 4, 6 and 8 hours post dose on Day 1 of Cycle 2

  14. Tmax of Crizotinib Metabolite PF-06260182 in The Presence of Avelumab

    Tmax of crizotinib metabolite PF-06260182 in the presence of avelumab was observed directly from data as time of first occurrence.

    Time frame: Pre-dose, 1, 2, 4, 6 and 8 hours post dose on Day 1 of Cycle 2

  15. AUCtau of Crizotinib Metabolite PF-06260182 in The Presence of Avelumab

    AUCtau of crizotinib metabolite PF-06260182 in the presence of avelumab was calculated by Linear/Log trapezoidal method. Dose interval: single dose from time zero to the next dose (after single dose and at steady state).

    Time frame: Pre-dose, 1, 2, 4, 6 and 8 hours post dose on Day 1 of Cycle 2

  16. Metabolite to Parent Ratio for AUCtau (MRAUCtau) of PF-06260182 in The Presence of Avelumab

    MRAUCtau of metabolite PF-06260182 in the presence of avelumab was calculated (MRAUCtau=Metabolite AUCtau/parent AUCtau). Parent=crizotinib, metabolite=PF-06260182

    Time frame: Pre-dose, 1, 2, 4, 6 and 8 hours post dose on Day 1 of Cycle 2

  17. Metabolite to Parent Ratio for Cmax (MRCmax) of PF-06260182 in The Presence of Avelumab

    MRCmax of metabolite PF-06260182 in the presence of avelumab was calculated (MRCmax=Metabolite Cmax/parent Cmax). Parent=crizotinib, metabolite=PF-06260182

    Time frame: Pre-dose, 1, 2, 4, 6 and 8 hours post dose on Day 1 of Cycle 2

  18. Cmax of Lorlatinib in The Presence of Avelumab

    Cmax of lorlatinib in the presence of avelumab was observed directly from data.

    Time frame: Pre-dose, 1, 2, 4, 6, 8, and 24 hours (prior to Day 2 lorlatinib dose) post dose on Day 1 of Cycle 2

  19. Tmax of Lorlatinib in The Presence of Avelumab

    Tmax of lorlatinib in the presence of avelumab was observed directly from data.

    Time frame: Pre-dose, 1, 2, 4, 6, 8, and 24 hours (prior to Day 2 lorlatinib dose) post dose on Day 1 of Cycle 2

  20. AUCtau of Lorlatinib in The Presence of Avelumab

    AUCtau of lorlatinib in the presence of avelumab was calculated by Linear/Log trapezoidal method. Dose interval: single dose from time zero to the next dose (after single dose and at steady state).

    Time frame: Pre-dose, 1, 2, 4, 6, 8, and 24 hours (prior to Day 2 lorlatinib dose) post dose on Day 1 of Cycle 2

  21. Area Under The Plasma Concentration Time Curve From Time of Dosing to The Last Collection Time Point (AUClast) of Lorlatinib in The Presence of Avelumab

    AUClast of lorlatinib in the presence of avelumab.

    Time frame: Pre-dose, 1, 2, 4, 6, 8, and 24 hours (prior to Day 2 lorlatinib dose) post dose on Day 1 of Cycle 2

  22. CL/F of Lorlatinib in The Presence of Avelumab

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population PK modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

    Time frame: Pre-dose, 1, 2, 4, 6, 8, and 24 hours (prior to Day 2 lorlatinib dose) post dose on Day 1 of Cycle 2

  23. Cmax of Avelumab in The Presence of Crizotinib (Group A) or Lorlatinib (Group B) After Single Dose of Avelumab

    Cmax of avelumab in the presence of crizotinib was observed directly from the data in Group A. Cmax of avelumab in the presence of lorlatinib was observed directly from the data in Group B.

    Time frame: Pre-dose, 1, and 168 hours post dose of avelumab on Cycle 1 Day 1.

  24. Cmax of Avelumab in The Presence of Crizotinib (Group A) or Lorlatinib (Group B) After Multiple Doses of Avelumab

    Cmax of avelumab in the presence of crizotinib was observed directly from the data in Group A. Cmax of avelumab in the presence of lorlatinib was observed directly from the data in Group B.

    Time frame: Pre-dose, 1, and 168 hours post dose of avelumab on Cycle 2 Day 1

  25. Trough Serum Concentration (Ctrough) of Avelumab in The Presence of Crizotinib (Group A) Following Multiple Doses of Avelumab

    Ctrough is defined as predose concentration following multiple doses. Ctrough of avelumab in the presence of crizotinib was observed directly from the data in Group A.

    Time frame: Pre-dose on Day 1 of Cycles 2-5, 11, 17, 23, 29, 35, and 47.

  26. Trough Serum Concentration (Ctrough) of Avelumab in The Presence of Lorlatinib (Group B) Following Multiple Doses of Avelumab

    Ctrough is defined as predose concentration following multiple doses. Ctrough of avelumab in the presence of lorlatinib was observed directly from the data in Group B.

    Time frame: Pre-dose on Day 1 of Cycles 2-5, 11, 17, 23, 29, 35, 41, and 47.

  27. Number of Participants With Anti-Drug Antibodies (ADA) Against Avelumab by Never and Ever Positive Status

    ADA never-positive was defined as no positive ADA results at any time point. ADA ever-positive was defined as at least one positive ADA result at any time point. Baseline is defined as the last assessment on or prior to the date/time of the first dose of avelumab.

    Time frame: Day 1 of Cycles 1-5, then every 12 weeks thereafter, end of treatment/withdrawal, and 30 days after last avelumab dose (up to a maximum of 5 years)

  28. Number of Participants With Positive Programmed Death Ligand-1 (PD-L1) Biomarker Expression

    PD-L1 protein expression is determined by using Combined Positive Score (CPS), which is the percentage of viable tumor and tumor-infiltrated immune cells (restricted to lymphocytes and macrophages) within or directly associated with tumor cell strands showing partial or complete membrane staining using the SP263 antibody. Positive is defined as CPS\>=1% and negative is defined as CPS \<1%.

    Time frame: Baseline

  29. Number of Participants With Positive Tumor Infiltrating CD8+ Lymphocytes

    Tumor infiltrating CD8+ lymphocytes is defined as the number of CD8+ cells per unit area and the percent of counted cells. Positive is defined as \>=1% and negative is defined as \<1%.

    Time frame: Baseline

07

Results

Posted Feb 9, 2022
Limitations and caveats
Enrollment in the study was terminated early based on the changing landscape in treatment options for treatment naïve ALK positive NSCLC. This decision was not due to any safety concerns or regulatory interactions. All participants on active treatment at the time of the early enrollment termination could continue treatment and follow up per the protocol.

Participant flow

Participant flow — Overall Study
MilestoneGroup A: Avelumab + CrizotinibGroup B: Avelumab + Lorlatinib
Started1231
Completed00
Not completed1231
Withdrew: Adverse event35
Withdrew: Death01
Withdrew: Lost to follow-up01
Withdrew: Physician decision12
Withdrew: Progressive disease715
Withdrew: Withdrawal by subject11
Withdrew: Other06

Outcome measures

PrimaryNumber of Participants With Dose-limiting Toxicities (DLTs): Phase 1b

Any of the following adverse events (AEs) occurring during the primary DLT observation period that are attributable to one, the other, or both study drugs were classified as DLTs: Grade 4 (life-threatening) neutropenia if \>7 days in duration; febrile neutropenia; Grade \>=3 (severe or life threatening) neutropenic infection; Grade \>=3 thrombocytopenia with bleeding; Grade 4 thrombocytopenia \>7 days; Grade 4 anemia; any Grade \>=3 toxicity, except for any of the following: transient (\<=6 hours) Grade 3 (severe) flu like symptoms or fever; transient (\<=24 hours) Grade 3 fatigue, local reactions, or headache that resolved to Grade \<=1 (no AE or mild AE); Grade 3 nausea and/or vomiting, diarrhea or skin toxicity that resolved to Grade \<=1 within 7 days; any Grade \>=3 amylase or lipase abnormality; tumor flare phenomenon; single laboratory values out of normal range that were not related to treatment, did not have any clinical correlate, and resolve to Grade \<=1 within 7 days.

Time frame:
First 2 cycles (1 cycle = 14 days)
Reported as:
Count of participants · Participants
Number of Participants With Dose-limiting Toxicities (DLTs): Phase 1b
ParticipantsGroup A: Avelumab + CrizotinibGroup B: Avelumab + Lorlatinib
Number of Participants With Dose-limiting Toxicities (DLTs): Phase 1b52
PrimaryPercentage of Participants With Objective Response (OR): Phase 2

OR is defined as complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 from start date (the date of first dose of study treatment) until disease progression or death due to any cause. Both CR and PR must be confirmed by repeat assessments performed no less than 4 weeks after the criteria for response are first met. Per RECIST v1.1: CR is defined as the disappearance of all target or non-target lesions; any pathological lymph nodes (whether target or non target) must have reduction in short axis to \<10 mm and all lymph nodes must be non-pathological in size (\<10 mm short axis). PR is defined as a \>=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.

Time frame:
Screening, Day 1 of each cycle starting Cycle 3, up to end of treatment/withdrawal (maximum of 5 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Objective Response (OR): Phase 2
Percentage of participantsGroup A: Avelumab + CrizotinibGroup B: Avelumab + Lorlatinib
Percentage of Participants With Objective Response (OR): Phase 225.0 (5.5 to 57.2)51.6 (33.1 to 69.8)
PrimaryPercentage of Participants With CR for Group B: Phase 2

Per RECIST v1.1: CR is defined as the disappearance of all target or non-target lesions; any pathological lymph nodes (whether target or non target) must have reduction in short axis to \<10 mm and all lymph nodes must be non-pathological in size (\<10 mm short axis).

Time frame:
Baseline up to 60 months
Reported as:
Number · Percentage of participants
Percentage of Participants With CR for Group B: Phase 2
Percentage of participantsGroup B: Avelumab + Lorlatinib
Percentage of Participants With CR for Group B: Phase 23.2
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

TEAEs are those events with onset dates occurring during the on-treatment period for the first time, or if the worsening of an event is during the on-treatment period. Treatment-related AEs was any untoward medical occurrence attributed to study drug in a participant who received study drug. Per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03: Grade 3 (Severe) events=unacceptable or intolerable events, significantly interrupting usual daily activity, require systemic drug therapy/other treatment; Grade 4 (Life-threatening) events caused participant to be in imminent danger of death; Grade 5 (Death) events=death related to an AE. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in participant hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

Time frame:
Baseline up to 30 days after last dose of study treatment or the day before start day of new anti-cancer therapy (maximum of 5 years)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsGroup A: Avelumab + CrizotinibGroup B: Avelumab + Lorlatinib
Participants with TEAEs1230
Participants with Grade >= 3 TEAEs723
Participants with treatment-related TEAEs1228
Participants with Grade >= 3 treatment-related TEAEs616
Participants with SAEs521
Participants with treatment-related SAEs26
Participants with TEAEs leading to discontinuation of avelumab310
Participants with TEAEs leading to discontinuation of crizotinib6—
Participants with TEAEs leading to discontinuation of lorlatinib—2
Participants with TEAEs leading to discontinuation of any study drug610
Participants with TEAEs leading to discontinuation of all study drugs31
Participants with treatment-related TEAEs leading to discontinuation of avelumab29
Participants with treatment-related TEAEs leading to discontinuation of crizotinib5—
Participants with treatment-related TEAEs leading to discontinuation of lorlatinib—2
Participants with TEAEs leading to death14
Participants with treatment-related TEAEs leading to death01
Participants with infusion-related reactions59
SecondaryNumber of Participants With Baseline Laboratory Abnormalities Grade <=2 and Post-Baseline Laboratory Abnormalities of Grades 3 or 4 Per NCI CTCAE v4.03

The laboratory results were graded according to the NCI CTCAE v4.03 severity grade. Grade 1=mild AE. Grade 2=moderate AE. Grade 3=severe AE. Grade 4=life-threatening consequences; urgent intervention indicated. Shift tables were provided to examine the distribution of laboratory toxicities. The following parameters had met the criteria of CTCAE grade shift change from Grade \<=2 at baseline to Grade 3 or 4 post baseline: anemia, lymphocyte count decreased, lymphocyte count decreased, neutrophil count decreased, white blood cell decreased, alanine aminotransferase increased, aspartate aminotransferase increased, blood bilirubin increased, cholesterol high, Creatine phosphokinase (CPK) increased, Gamma glutamyl transferase (GGT) increased, hypercalcemia, hyperglycemia, hypermagnesemia, hypertriglyceridemia, hypoalbuminemia, hyponatremia, lipase increased, serum amylase increased. Baseline is defined as the last assessment prior to the date/time of the first dose of study treatment.

Time frame:
Screening up to end of treatment/withdrawal (maximum of 5 years)
Reported as:
Count of participants · Participants
Number of Participants With Baseline Laboratory Abnormalities Grade <=2 and Post-Baseline Laboratory Abnormalities of Grades 3 or 4 Per NCI CTCAE v4.03
ParticipantsGroup A: Avelumab + CrizotinibGroup B: Avelumab + Lorlatinib
Anemia03
Lymphocyte count decreased12
Lymphocyte count increased02
Neutrophil count decreased10
White blood cell decreased10
Alanine aminotransferase increased30
Aspartate aminotransferase increased21
Blood bilirubin increased01
Cholesterol high05
CPK increased02
GGT increased15
Hypercalcemia02
Hyperglycemia11
Hypermagnesemia01
Hypertriglyceridemia07
Hypoalbuminemia01
Hyponatremia13
Lipase increased15
Serum amylase increased01
Hemoglobin increased00
Platelet count decreased00
Alkaline phosphatase increased00
Creatinine increased00
Hyperkalemia00
Hypernatremia00
Hypocalcemia00
Hypoglycemia00
Hypokalemia00
Hypomagnesemia00
Hypophosphatemia00
SecondaryNumber of Participants With Vital Signs Meeting Pre-defined Criteria

Pre-defined criteria in vital signs: pulse rate \<50 beats per minute, pulse rate \>120 bpm, sitting diastolic blood pressure (DBP) increase and decrease in change from baseline of \>= 20 millimeter of mercury (mmHg), sitting systolic blood pressure(SBP) \< 90 mmHg, increase and decrease in change from baseline of \>= 30mmHg. Baseline is defined as the last assessment prior to the date/time of the first dose of study treatment.

Time frame:
Screening up to end of treatment/withdrawal (maximum of 5 years)
Reported as:
Count of participants · Participants
Number of Participants With Vital Signs Meeting Pre-defined Criteria
ParticipantsGroup A: Avelumab + CrizotinibGroup B: Avelumab + Lorlatinib
Pulse rate <50 bpm20
Pulse rate >120 bpm04
Sitting DBP change >= 20 mmHg increase213
Sitting DBP change >= 20 mmHg decrease58
Sitting SBP <90 mmHg14
Sitting SBP change >= 30 mmHg increase111
Sitting SBP change >= 30 mmHg decrease32
SecondaryDisease Control Rate (DCR)

DC is defined as objective response (CR or PR) or stable disease (SD) per RECIST v.1.1 from the date of first dose of study treatment until disease progression or death due to any cause. The DCR is the proportion of patients with DC. Per RECIST v1.1: CR is defined as the disappearance of all target or non-target lesions; any pathological lymph nodes (whether target or non target) must have reduction in short axis to \<10 mm. PR is defined as a \>=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD). PD is defined as a \>=20% increase in the sum of the longest dimensions of the target lesions taking as a reference the smallest sum of the longest dimensions recorded since the treatment started, or the appearance of one or more new lesions.

Time frame:
Screening, Day 1 of each cycle starting Cycle 3, up to end of treatment/withdrawal (maximum of 5 years)
Reported as:
Number · Percentage of participants
Disease Control Rate (DCR)
Percentage of participantsGroup A: Avelumab + CrizotinibGroup B: Avelumab + Lorlatinib
Disease Control Rate (DCR)58.3 (27.7 to 84.8)71.0 (52.0 to 85.8)
SecondaryDuration of Response (DR)

DR: time from first documented occurrence of response (PR or CR) until date of first documented PD or death due to underlying cancer. Per RECIST 1.1: CR: disappearance of all non-nodal target lesions and of all non-target lesions; any pathological lymph nodes assigned as target lesions/non-target lesions have a reduction in short axis to \<10 mm. PR: at least a \>=30% decrease in sum of diameter of all target lesions, taking as reference baseline sum of diameters. PD: at least a \>=20% increase in sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, sum must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of existing non-target lesions. Appearance of new lesions. Participants with no PD and were still alive by 02 Feb 2020, were censored at last adequate tumor assessment. Kaplan-Meier method was used for DR analysis.

Time frame:
Screening, Day 1 of each cycle starting Cycle 3, up to end of treatment/withdrawal (maximum of 5 years)
Reported as:
Median · Month
Duration of Response (DR)
MonthGroup A: Avelumab + CrizotinibGroup B: Avelumab + Lorlatinib
Duration of Response (DR)3.7 (3.7 to 4.6)14.7 (3.7 to NA)
SecondaryTime to Tumor Response (TTR)

TTR is defined, for participants with an objective response (CR or PR), as the time from the start date (the date of first dose of treatment) to the first documentation of objective response (CR or PR) which is subsequently confirmed. Per RECIST v1.1: CR: disappearance of all non-nodal target lesions and of all non-target lesions. In addition, any pathological lymph nodes assigned as target lesions/ non-target lesions must have a reduction in short axis to \<10 mm. PR: at least a 30% decrease in sum of diameter of all target lesions, taking as reference baseline sum of diameters.

Time frame:
Screening, Day 1 of each cycle starting Cycle 3, up to end of treatment/withdrawal (maximum of 5 years)
Reported as:
Median · Months
Time to Tumor Response (TTR)
MonthsGroup A: Avelumab + CrizotinibGroup B: Avelumab + Lorlatinib
Time to Tumor Response (TTR)1.4 (1.4 to 6.9)1.8 (1.3 to 3.7)
SecondaryProgression-free Survival (PFS)

PFS is defined as the time from start date (the date of first dose of treatment) to the date of the first documentation of PD per RECIST v1.1 or death due to any cause, whichever occurs first. Per RECIST v1.1: PD: a \>=20% increase in the sum of the longest dimensions of the target lesions taking as a reference the smallest sum of the longest dimensions recorded since the treatment started, or the appearance of one or more new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
Screening, Day 1 of each cycle starting Cycle 3, up to end of treatment/withdrawal (maximum of 5 years)
Reported as:
Median · Months
Progression-free Survival (PFS)
MonthsGroup A: Avelumab + CrizotinibGroup B: Avelumab + Lorlatinib
Progression-free Survival (PFS)3.7 (1.5 to 5.5)6.4 (3.7 to 9.2)
SecondaryKaplan-Meier Estimates of Overall Survival (OS)

OS is defined as the time from start date (the date of first dose of treatment) to the date of death due to any cause.

Time frame:
Screening, Day 1 of each cycle starting Cycle 3, up to end of treatment/withdrawal (maximum of 5 years)
Reported as:
Median · Months
Kaplan-Meier Estimates of Overall Survival (OS)
MonthsGroup A: Avelumab + CrizotinibGroup B: Avelumab + Lorlatinib
Kaplan-Meier Estimates of Overall Survival (OS)16.4 (5.4 to 27.6)32.9 (10.7 to NA)
SecondaryMaximum Plasma Concentration (Cmax) of Crizotinib in The Presence of Avelumab

Cmax of crizotinib in the presence of avelumab was observed directly from data.

Time frame:
Pre-dose, 1, 2, 4, 6 and 8 hours post dose on Day 1 of Cycle 2
Reported as:
Geometric mean · nanograms per millilitre (ng/mL)
Maximum Plasma Concentration (Cmax) of Crizotinib in The Presence of Avelumab
nanograms per millilitre (ng/mL)Group A: Avelumab + Crizotinib
Maximum Plasma Concentration (Cmax) of Crizotinib in The Presence of Avelumab281 ± 74
SecondaryTime to Cmax (Tmax) of Crizotinib in The Presence of Avelumab

Tmax of crizotinib in the presence of avelumab was observed directly from data as time of first occurrence.

Time frame:
Pre-dose, 1, 2, 4, 6 and 8 hours post dose on Day 1 of Cycle 2
Reported as:
Median · Hours
Time to Cmax (Tmax) of Crizotinib in The Presence of Avelumab
HoursGroup A: Avelumab + Crizotinib
Time to Cmax (Tmax) of Crizotinib in The Presence of Avelumab2.03 (0.00 to 8.08)
SecondaryArea Under The Plasma Concentration-Time Curve During The Dosing Interval Time Course (AUCtau) of Crizotinib in The Presence of Avelumab

AUCtau of crizotinib in the presence of avelumab was calculated by Linear/Log trapezoidal method. Dose interval is defined as after single dose from time zero to the next dose (after single dose and at steady state).

Time frame:
Pre-dose, 1, 2, 4, 6 and 8 hours post dose on Day 1 of Cycle 2
Reported as:
Geometric mean · nanograms*hours per millilitre (ng*h/mL)
Area Under The Plasma Concentration-Time Curve During The Dosing Interval Time Course (AUCtau) of Crizotinib in The Presence of Avelumab
nanograms*hours per millilitre (ng*h/mL)Group A: Avelumab + Crizotinib
Area Under The Plasma Concentration-Time Curve During The Dosing Interval Time Course (AUCtau) of Crizotinib in The Presence of Avelumab2755 ± 82
SecondaryApparent Plasma Clearance (CL/F) of Crizotinib in The Presence of Avelumab

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

Time frame:
Pre-dose, 1, 2, 4, 6 and 8 hours post dose on Day 1 of Cycle 2
Reported as:
Geometric mean · Liter per hour (L/h)
Apparent Plasma Clearance (CL/F) of Crizotinib in The Presence of Avelumab
Liter per hour (L/h)Group A: Avelumab + Crizotinib
Apparent Plasma Clearance (CL/F) of Crizotinib in The Presence of Avelumab90.76 ± 82
SecondaryCmax of Crizotinib Metabolite PF-06260182 in The Presence of Avelumab

Cmax of crizotinib metabolite PF-06260182 in the presence of avelumab was observed directly from data.

Time frame:
Pre-dose, 1, 2, 4, 6 and 8 hours post dose on Day 1 of Cycle 2
Reported as:
Geometric mean · ng/mL
Cmax of Crizotinib Metabolite PF-06260182 in The Presence of Avelumab
ng/mLGroup A: Avelumab + Crizotinib
Cmax of Crizotinib Metabolite PF-06260182 in The Presence of Avelumab84.11 ± 91
SecondaryTmax of Crizotinib Metabolite PF-06260182 in The Presence of Avelumab

Tmax of crizotinib metabolite PF-06260182 in the presence of avelumab was observed directly from data as time of first occurrence.

Time frame:
Pre-dose, 1, 2, 4, 6 and 8 hours post dose on Day 1 of Cycle 2
Reported as:
Median · Hours
Tmax of Crizotinib Metabolite PF-06260182 in The Presence of Avelumab
HoursGroup A: Avelumab + Crizotinib
Tmax of Crizotinib Metabolite PF-06260182 in The Presence of Avelumab3.02 (0.00 to 8.08)
SecondaryAUCtau of Crizotinib Metabolite PF-06260182 in The Presence of Avelumab

AUCtau of crizotinib metabolite PF-06260182 in the presence of avelumab was calculated by Linear/Log trapezoidal method. Dose interval: single dose from time zero to the next dose (after single dose and at steady state).

Time frame:
Pre-dose, 1, 2, 4, 6 and 8 hours post dose on Day 1 of Cycle 2
Reported as:
Geometric mean · ng*h/mL
AUCtau of Crizotinib Metabolite PF-06260182 in The Presence of Avelumab
ng*h/mLGroup A: Avelumab + Crizotinib
AUCtau of Crizotinib Metabolite PF-06260182 in The Presence of Avelumab789.1 ± 116
SecondaryMetabolite to Parent Ratio for AUCtau (MRAUCtau) of PF-06260182 in The Presence of Avelumab

MRAUCtau of metabolite PF-06260182 in the presence of avelumab was calculated (MRAUCtau=Metabolite AUCtau/parent AUCtau). Parent=crizotinib, metabolite=PF-06260182

Time frame:
Pre-dose, 1, 2, 4, 6 and 8 hours post dose on Day 1 of Cycle 2
Reported as:
Geometric mean · Ratio
Metabolite to Parent Ratio for AUCtau (MRAUCtau) of PF-06260182 in The Presence of Avelumab
RatioGroup A: Avelumab + Crizotinib
Metabolite to Parent Ratio for AUCtau (MRAUCtau) of PF-06260182 in The Presence of Avelumab0.2779 ± 33
SecondaryMetabolite to Parent Ratio for Cmax (MRCmax) of PF-06260182 in The Presence of Avelumab

MRCmax of metabolite PF-06260182 in the presence of avelumab was calculated (MRCmax=Metabolite Cmax/parent Cmax). Parent=crizotinib, metabolite=PF-06260182

Time frame:
Pre-dose, 1, 2, 4, 6 and 8 hours post dose on Day 1 of Cycle 2
Reported as:
Geometric mean · Ratio
Metabolite to Parent Ratio for Cmax (MRCmax) of PF-06260182 in The Presence of Avelumab
RatioGroup A: Avelumab + Crizotinib
Metabolite to Parent Ratio for Cmax (MRCmax) of PF-06260182 in The Presence of Avelumab0.2902 ± 25
SecondaryCmax of Lorlatinib in The Presence of Avelumab

Cmax of lorlatinib in the presence of avelumab was observed directly from data.

Time frame:
Pre-dose, 1, 2, 4, 6, 8, and 24 hours (prior to Day 2 lorlatinib dose) post dose on Day 1 of Cycle 2
Reported as:
Geometric mean · ng/mL
Cmax of Lorlatinib in The Presence of Avelumab
ng/mLGroup B: Avelumab + Lorlatinib
Cmax of Lorlatinib in The Presence of Avelumab596.9 ± 33
SecondaryTmax of Lorlatinib in The Presence of Avelumab

Tmax of lorlatinib in the presence of avelumab was observed directly from data.

Time frame:
Pre-dose, 1, 2, 4, 6, 8, and 24 hours (prior to Day 2 lorlatinib dose) post dose on Day 1 of Cycle 2
Reported as:
Median · Hours
Tmax of Lorlatinib in The Presence of Avelumab
HoursGroup B: Avelumab + Lorlatinib
Tmax of Lorlatinib in The Presence of Avelumab1.23 (0.933 to 4.33)
SecondaryAUCtau of Lorlatinib in The Presence of Avelumab

AUCtau of lorlatinib in the presence of avelumab was calculated by Linear/Log trapezoidal method. Dose interval: single dose from time zero to the next dose (after single dose and at steady state).

Time frame:
Pre-dose, 1, 2, 4, 6, 8, and 24 hours (prior to Day 2 lorlatinib dose) post dose on Day 1 of Cycle 2
Reported as:
Geometric mean · ng*h/mL
AUCtau of Lorlatinib in The Presence of Avelumab
ng*h/mLGroup B: Avelumab + Lorlatinib
AUCtau of Lorlatinib in The Presence of Avelumab5807 ± 42
SecondaryArea Under The Plasma Concentration Time Curve From Time of Dosing to The Last Collection Time Point (AUClast) of Lorlatinib in The Presence of Avelumab

AUClast of lorlatinib in the presence of avelumab.

Time frame:
Pre-dose, 1, 2, 4, 6, 8, and 24 hours (prior to Day 2 lorlatinib dose) post dose on Day 1 of Cycle 2
Reported as:
Geometric mean · ng*h/mL
Area Under The Plasma Concentration Time Curve From Time of Dosing to The Last Collection Time Point (AUClast) of Lorlatinib in The Presence of Avelumab
ng*h/mLGroup B: Avelumab + Lorlatinib
Area Under The Plasma Concentration Time Curve From Time of Dosing to The Last Collection Time Point (AUClast) of Lorlatinib in The Presence of Avelumab4872 ± 52
SecondaryCL/F of Lorlatinib in The Presence of Avelumab

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population PK modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

Time frame:
Pre-dose, 1, 2, 4, 6, 8, and 24 hours (prior to Day 2 lorlatinib dose) post dose on Day 1 of Cycle 2
Reported as:
Geometric mean · L/h
CL/F of Lorlatinib in The Presence of Avelumab
L/hGroup B: Avelumab + Lorlatinib
CL/F of Lorlatinib in The Presence of Avelumab16.97 ± 44
SecondaryCmax of Avelumab in The Presence of Crizotinib (Group A) or Lorlatinib (Group B) After Single Dose of Avelumab

Cmax of avelumab in the presence of crizotinib was observed directly from the data in Group A. Cmax of avelumab in the presence of lorlatinib was observed directly from the data in Group B.

Time frame:
Pre-dose, 1, and 168 hours post dose of avelumab on Cycle 1 Day 1.
Reported as:
Geometric mean · micrograms/milliliter (ug/mL)
Cmax of Avelumab in The Presence of Crizotinib (Group A) or Lorlatinib (Group B) After Single Dose of Avelumab
micrograms/milliliter (ug/mL)Group A: Avelumab + CrizotinibGroup B: Avelumab + Lorlatinib
Cmax of Avelumab in The Presence of Crizotinib (Group A) or Lorlatinib (Group B) After Single Dose of Avelumab193.2 ± 14195.7 ± 28
SecondaryCmax of Avelumab in The Presence of Crizotinib (Group A) or Lorlatinib (Group B) After Multiple Doses of Avelumab

Cmax of avelumab in the presence of crizotinib was observed directly from the data in Group A. Cmax of avelumab in the presence of lorlatinib was observed directly from the data in Group B.

Time frame:
Pre-dose, 1, and 168 hours post dose of avelumab on Cycle 2 Day 1
Reported as:
Geometric mean · ug/mL
Cmax of Avelumab in The Presence of Crizotinib (Group A) or Lorlatinib (Group B) After Multiple Doses of Avelumab
ug/mLGroup A: Avelumab + CrizotinibGroup B: Avelumab + Lorlatinib
Cmax of Avelumab in The Presence of Crizotinib (Group A) or Lorlatinib (Group B) After Multiple Doses of Avelumab174.5 ± 35169.4 ± 68
SecondaryTrough Serum Concentration (Ctrough) of Avelumab in The Presence of Crizotinib (Group A) Following Multiple Doses of Avelumab

Ctrough is defined as predose concentration following multiple doses. Ctrough of avelumab in the presence of crizotinib was observed directly from the data in Group A.

Time frame:
Pre-dose on Day 1 of Cycles 2-5, 11, 17, 23, 29, 35, and 47.
Reported as:
Geometric mean · ug/mL
Trough Serum Concentration (Ctrough) of Avelumab in The Presence of Crizotinib (Group A) Following Multiple Doses of Avelumab
ug/mLGroup A: Avelumab + Crizotinib
Cycle 2 Day 111.76 ± 68
Cycle 3 Day 116.26 ± 53
Cycle 4 Day 116.71 ± 34
Cycle 5 Day 114.21 ± 46
Cycle 11 Day 126.64 ± 4
Cycle 17 Day 130.59 ± 9
Cycle 23 Day 130.63 ± 15
Cycle 29 Day 130.72 ± 55
Cycle 35 Day 137.31 ± 27
Cycle 47 Day 140.91 ± 15
SecondaryTrough Serum Concentration (Ctrough) of Avelumab in The Presence of Lorlatinib (Group B) Following Multiple Doses of Avelumab

Ctrough is defined as predose concentration following multiple doses. Ctrough of avelumab in the presence of lorlatinib was observed directly from the data in Group B.

Time frame:
Pre-dose on Day 1 of Cycles 2-5, 11, 17, 23, 29, 35, 41, and 47.
Reported as:
Geometric mean · ug/mL
Trough Serum Concentration (Ctrough) of Avelumab in The Presence of Lorlatinib (Group B) Following Multiple Doses of Avelumab
ug/mLGroup B: Avelumab + Lorlatinib
Cycle 2 Day 116.86 ± 88
Cycle 3 Day 116.99 ± 116
Cycle 4 Day 123.71 ± 80
Cycle 5 Day 126.74 ± 68
Cycle 11 Day 131.31 ± 71
Cycle 17 Day 132.69 ± 60
Cycle 23 Day 133.20 ± 56
Cycle 29 Day 125.77 ± 66
Cycle 35 Day 131.27 ± 47
Cycle 41 Day 130.81 ± 59
Cycle 47 Day 139.63 ± 64
SecondaryNumber of Participants With Anti-Drug Antibodies (ADA) Against Avelumab by Never and Ever Positive Status

ADA never-positive was defined as no positive ADA results at any time point. ADA ever-positive was defined as at least one positive ADA result at any time point. Baseline is defined as the last assessment on or prior to the date/time of the first dose of avelumab.

Time frame:
Day 1 of Cycles 1-5, then every 12 weeks thereafter, end of treatment/withdrawal, and 30 days after last avelumab dose (up to a maximum of 5 years)
Reported as:
Count of participants · Participants
Number of Participants With Anti-Drug Antibodies (ADA) Against Avelumab by Never and Ever Positive Status
ParticipantsGroup A: Avelumab + CrizotinibGroup B: Avelumab + LorlatinibAll Participants
ADA never-positive92534
ADA ever-positive369
SecondaryNumber of Participants With Positive Programmed Death Ligand-1 (PD-L1) Biomarker Expression

PD-L1 protein expression is determined by using Combined Positive Score (CPS), which is the percentage of viable tumor and tumor-infiltrated immune cells (restricted to lymphocytes and macrophages) within or directly associated with tumor cell strands showing partial or complete membrane staining using the SP263 antibody. Positive is defined as CPS\>=1% and negative is defined as CPS \<1%.

Time frame:
Baseline
Reported as:
Count of participants · Participants
Number of Participants With Positive Programmed Death Ligand-1 (PD-L1) Biomarker Expression
ParticipantsGroup A: Avelumab + CrizotinibGroup B: Avelumab + Lorlatinib
Positive720
Negative24
SecondaryNumber of Participants With Positive Tumor Infiltrating CD8+ Lymphocytes

Tumor infiltrating CD8+ lymphocytes is defined as the number of CD8+ cells per unit area and the percent of counted cells. Positive is defined as \>=1% and negative is defined as \<1%.

Time frame:
Baseline
Reported as:
Count of participants · Participants
Number of Participants With Positive Tumor Infiltrating CD8+ Lymphocytes
ParticipantsGroup A: Avelumab + CrizotinibGroup B: Avelumab + Lorlatinib
Positive64
Negative418

Adverse events

Collected over Baseline up to 30 days post lost dose of study treatment with a maximum of 5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group A: Avelumab + Crizotinib10/12 (83.3%)5/12 (41.7%)12/12 (100%)
Group B: Avelumab + Lorlatinib15/31 (48.4%)21/31 (67.7%)28/31 (90.3%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventGroup A: Avelumab + CrizotinibGroup B: Avelumab + Lorlatinib
PneumoniaInfections and infestations0/123/31
Febrile neutropeniaBlood and lymphatic system disorders1/120/31
Disease progressionGeneral disorders1/120/31
Immune-mediated hepatitisHepatobiliary disorders1/120/31
PneumonitisRespiratory, thoracic and mediastinal disorders1/122/31
PneumothoraxRespiratory, thoracic and mediastinal disorders1/120/31
RashSkin and subcutaneous tissue disorders1/120/31
Confusional statePsychiatric disorders0/122/31
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/122/31
Cardiac tamponadeCardiac disorders0/121/31
Most frequent other events
Showing 10 of 117
Most frequent other events
EventGroup A: Avelumab + CrizotinibGroup B: Avelumab + Lorlatinib
Blood cholesterol increasedInvestigations0/1219/31
NauseaGastrointestinal disorders7/125/31
HypertriglyceridaemiaMetabolism and nutrition disorders0/1218/31
VomitingGastrointestinal disorders6/126/31
ArthralgiaMusculoskeletal and connective tissue disorders0/1213/31
Decreased appetiteMetabolism and nutrition disorders5/122/31
Oedema peripheralGeneral disorders1/1212/31
Alanine aminotransferase increasedInvestigations4/129/31
RashSkin and subcutaneous tissue disorders4/125/31
HypothyroidismEndocrine disorders0/128/31

Baseline characteristics

The baseline analysis population included all participants who received at least one dose of study drug. Participants were classified according to the study treatment actually received. If a participant received more than one treatment the participant was classified according to the first treatment received.

Age, Continuous
Age, Continuous(Years)Group A: Avelumab + CrizotinibGroup B: Avelumab + LorlatinibTotal
Mean58.67 ± 10.4353.32 ± 11.5954.81 ± 11.41
Age, Customized
Age, Customized(Participants)Group A: Avelumab + CrizotinibGroup B: Avelumab + LorlatinibTotal
<65 years9257
65-<75 years252
75-<85 years112
Sex: Female, Male
Sex: Female, Male(Participants)Group A: Avelumab + CrizotinibGroup B: Avelumab + LorlatinibTotal
Female61925
Male61218
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Group A: Avelumab + CrizotinibGroup B: Avelumab + LorlatinibTotal
American Indian or Alaska Native011
Asian81725
White41317
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Group A: Avelumab + CrizotinibGroup B: Avelumab + LorlatinibTotal
Hispanic or Latino011
Not Hispanic or Latino113041
Not Reported101
Age Range
Age Range(Years)Group A: Avelumab + CrizotinibGroup B: Avelumab + LorlatinibTotal
Median59.5 (43 to 76)54 (30 to 77)55 (30 to 77)
08

Study locations

20 sites
  • Emory University Hospital Midtown
    Atlanta, Georgia 30308, United States
  • Emory University Hospital
    Atlanta, Georgia 30322, United States
  • The Emory Clinic
    Atlanta, Georgia 30322, United States
  • Winship Cancer Institute of Emory University
    Atlanta, Georgia 30322, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114-2696, United States
  • Ophthalmic Consultants of Boston Inc (OCB)
    Boston, Massachusetts 02114, United States
  • Tennessee Oncology, PLLC
    Nashville, Tennessee 37203, United States
  • Chris O'Brien Lifehouse
    Camperdown, New South Wales 2050, Australia
  • The Prince Charles Hospital
    Chermside, Queensland 4032, Australia
  • Peter MacCallum Cancer Centre
    Melbourne, Victoria 3000, Australia
  • Royal Melbourne Hospital
    Parkville, Victoria 3050, Australia
  • Aichi cancer center central hospital
    Nagoya, Aichi 464-8681, Japan
  • National Hospital Organization Kyushu Cancer Center
    Fukuoka, 811-1395, Japan
  • The Cancer Institute Hospital of JFCR
    Koto-ku, Tokyo, 135-8550, Japan
  • National Cancer Center
    Goyang-Si, Gyeonggi-do 10408, Korea, Republic of
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • Institut Catala d'Oncologia de Badalona
    Badalona, Barcelona 08916, Spain
  • Hospital Quiron Barcelona
    Barcelona, 08023, Spain
  • Hospital Universitari de la Vall d'Hebron
    Barcelona, 08035, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2015 to primary completion in Feb 2021, 61 months.

Results were first posted in Feb 2022, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2015
First posted
Oct 22, 2015
StartActual
Dec 18, 2015
Primary completionActual
Feb 2, 2021
CompletionActual
Jul 13, 2022
Results first posted
Feb 9, 2022
Last update
Jul 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02584634
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Oct 22, 2015
Start date
Dec 18, 2015
Primary completion
Feb 2, 2021
Completion
Jul 13, 2022
Results posted
Feb 9, 2022
Last update
Jul 7, 2023

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lorlatinib

Start the discussion